Skip to main content

Table 1 Summary of included studies

From: Prognostic factors for overall survival in patients with spinal metastasis secondary to prostate cancer: a systematic review and meta-analysis

Study IDStudy periodCountryPatients (n)Patients with MSCCAge -median (range)Distribution of involved vertebraePSA (ng/ml) -median (range)Gleason scoreVisceral met.Other bone met.Involved vertebrae -nPerformance statusOverall survival (median values & OS%)hormone statusNOS
Ju, 2013 [15]2002–2011USA272765 (46–82)C-1,CT-3,T-3,TL-7,L-1,LS-1,S-0,C/T/L-5,T/L/S-650 (0.1–11,900)median: 8.5 (range, 6–10)1426NAKPS:
10–70:19;
80–100:8
1)10 (95%CI, 5–16)m;
2)OS%-1/3/6/9/24 m:
96/81/70/62/40
HR:24;
HN:3
8
Meng, 2016 [16]2002–2012China29NA71 (59–83)C-5,T-11,L-12,S-1NANA710NAKPS:
10–70:26;
80–100:3
1)44 (range,1–80)m;
2)OS%-12/24/60 m:
89.7/74.4/19.7
HR:9;
HN:20
7
Huddart, 1997 [21]1984–1992UK6969NAC-5,T-44,L/S-20NANANANA1:47;
≥2:20
NA1)4 (range, 0.2–67)m;
2)OS%-24 m: 25
NA8
Williams, 2009 [22]1993–2005USA444468 (51–85)C-1,CT-1,T-3,TL-11,L-4,LS-1,S-3,C/T/L-15,T/L/S-527.5 (2.4–1520)median: 8 (range, 2–10)3442NANA1)5 (95%CI, 1–10)m
2)NA
NA9
Rades, 2012 [23]1992–2010Germany436436NANANANA1002521–2:178;
≥3:258
ECOG:
1–2:220;
3–4:216
1)NA
2)OS%-6/12 m: 57.3/45.0
NA7
Crnalic, 2011 [24]2003–2008Sweden5454HR: 72 (54–88);
HN: 77 (60–85)
C-1,CT-1,T-43,L-9HR: 190 (0.5–5139);
HN: 140 (21–3704)
6:2; 7:15; 8:7; 9:7; 10:3; NA:2012521:35; 2:17; 3–4:2KPS (HR):
10–70:33;
80–100:8
1)HR: 5(range, 0–36)m;
2)OS%-1/3/6/12 m:
89/76/59/41
HR:41
HN:13
7
Drzymalski, 2010 [25]1990–2009USA3337768 (43–90)NA58.2 (0–19,572)≥7: 24637278NANA1)24 (95%CI,21–28)m;
2)OS%-12 m:73
NA8
Crnalic, 2012 [14]2003–2010Sweden6868HR: 71 (54–88);
HN: 77 (60–88)
NAHR:140 (0.06–5139);
HN:147 (21–10,000)
≤6:3; 7:19; 8:9; 9:9; 10:3; NA: 2517NANAKPS:
10–70:47;
80–100:21
1)NA
2)OS%-1,3,6,12,24 m: 89.7/72.1/57.4/44.1/23.5
HR:53;
HN:15
7
Zakaria, 2018 [26]2002–2012USA92NA73 (51–92)NANANANANA1:30; 2:24; 3–4:37NA1)4.1 (95%CI, 3.3–6.6)m;
2)NA
NA6
Rades, 2015 [27]NAGermany24324376NANANA651561–2:94;
3–4:84;
≥5:65
ECOG:
1–2:107;
3–4:136
1)NA;
2)OS%-6/12 m:58.4/46.9
NA6
Lehrmann-Lerche, 2019 [28]2010–2011Denmark767673.2 (50.6–95.8)C-5, T-53, L-41, S-18NA≤7:14; 8:18; ≥9:32; NA:12NA481:19;
2:19;
≥3:38
NA1)4.9 (95%CI, 3.6–6.2)m;
2)OS%-3/6/12 m:
64/42/21
NA8
Weber, 2013 [29]NAGermany9595NANANANA69NA1–2:27;
≥3:68
ECOG:
1–2:32;
3–4:63
1)NA;
2)OS%-6/12 m:57.9/46.3
NA7
  1. NA Not available, MSCC Metastatic spinal cord compression, OS% Percentage of overall survival, NOS Newcastle-Ottawa Scale, PSA Prostate-specific antigen, HR Hormone-refractory prostate cancer, HN Hormone-naive prostate cancer, KPS Karnofsky performance score, ECOG Eastern Cooperative Oncology Group. Distribution of involved vertebrae: C Cervical, CT Cervicothoracic, T Thoracic, TL Thoracolumbar, L Lumbar, LS Lumbosacral; S Sacral